{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344577","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2026-08-11T20:05:17+00:00","discovered_at":"2026-08-11T20:07:00.452790+00:00","generated_at":"2026-08-11T20:07:58.162559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome Q2 net loss $73.1M; FDA accepts varegacestat NDA, PDUFA April 28, 2027","bullets":["FDA accepted NDA for varegacestat in desmoid tumors; PDUFA target April 28, 2027.","Phase 3 RINGSIDE: 84% risk reduction (HR=0.16, p<0.0001); ORR 56% vs 9%.","Cash $520.0M as of June 30, 2026; expected to fund operations into 2028.","Q2 net loss $73.1M; R&D $59.9M, G&A $18.3M including stock comp.","First patients dosed in Phase 1 trials of IM-1617 (June 2026) and IM-3050 (July 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344577","json":"https://secwatch.observer/filing/0001193125-26-344577.json","markdown":"https://secwatch.observer/filing/0001193125-26-344577.md","text":"https://secwatch.observer/filing/0001193125-26-344577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/0001193125-26-344577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:07:58.162559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}